Xifeng Wu, M.D., Ph.D.
Director, Center for Public Health and Translational Genomics
Professor, Department of Epidemiology
Xifeng Wu, MD, PhD, is a Professor in the Department of Epidemiology. She received her medical degree from Shanghai Medical University in 1984 and her PhD from The University of Texas School of Public Health in 1994.
Dr. Wu has established a large, highly interactive, and multidisciplinary research program that bridges the field of epidemiology, genetics, molecular biology, statistics, and clinical/translational research. Her multifaceted research spans a wide range of topics including genetic susceptibility of cancer and the interactions of genetics with environment and energy balance, risk modeling for cancer development, prognosis, treatment response, and survivorship using an integrative approach, and malignant progression of premalignant lesions. Through the identification and validation of biomarkers that can be incorporated with epidemiological, clinical, phenotypic, and genetic information, she strives to create personalized risk prediction models to aid in assessing risk for developing cancer, identifying patients who would benefit from cancer prevention interventions, predicting treatment response and clinical outcomes, and improving survivorship and quality of life. One of her major efforts recently was to establish the MD Anderson Cancer Patient Cohort through biobanking of new MD Anderson patients and linking biospecimens to epidemiological and clinical data. This cohort is uniquely suited for patient outcome, survivorship, and quality of life research.
Dr. Wu is highly productive with over 270 peer-reviewed publications in top journals and book chapters. She is the principal investigator of multiple NCI-funded large epidemiological studies. She serves in numerous MD Anderson committees including the Institutional Review Board (IRB) Committee and the Cancer Survivorship Steering Committee. She has received many distinguished awards at MD Anderson, including the Faculty Scholar Award, the Margaret and James A. Elkins Jr. Faculty Achievement Award in Cancer Prevention, the Julie and Ben Rogers Award for Excellence in Research, and the Robert M. Chamberlain Distinguished Mentor Award.
Maria Alma Rodriguez, M.D.
Co-Director, Center for Public Health and Translational Genomics
Vice President of Medical Affairs, Office of the EVP, Physician-in-Chief
Maria Alma Rodriguez, MD, received her medical degree from the University of Texas Medical School at Houston and did her residency in Internal Medicine at the UT Health Sciences Center in San Antonio, Texas. She trained as a cancer specialist at the University of Arizona Cancer Center in Tucson, Arizona. She has been a clinician and clinical investigator at UT MD Anderson Cancer Center (MDACC) since 1986. Her expertise is in the treatment of patients with lymphomas. She has published articles, authored book chapters, and co-edited a book on the treatment of lymphomas. She completed a Fellowship of the National Association of Public Hospitals in 2006, and was named Fellow in Clinical Safety & Effectiveness at MDACC in 2007.
Dr. Rodriguez has served on numerous committees within the MDACC institution, including the Institutional Review Board (IRB) and Clinical Ethics Committee, and nationally on the Oncology Drugs Advisory Committee for the U.S. Food and Drug Administration, and the Ethics Committee of the American Society of Clinical Oncology. Currently, she serves on the Steering Committee of the National Comprehensive Cancer Network Lymphoma Database, and is Vice President of Medical Affairs at MDACC.
Dr. Rodriguez is Chair of the Cancer Survivorship Steering Committee. She has been leading the rapid evolvement of the Cancer Survivorship initiative at MDACC for the past two years. Dr. Rodriguez was recently appointed to the American Society of Clinical Oncology’s Survivorship Committee.
If you are interested in becoming a member of the MD Anderson Center for Public Health and Translational Genomics, please contact CTPHG@mdanderson.org.